Alopecia therapy gains FDA breakthrough status

• by Teraya Smith

• October 13, 2026

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

• by Kathryn Wighton

• June 30, 2026

• 3 min

JAMA Dermatology

• June 1, 2026

Hair Repigmentation Reported With Baricitinib in Canities Subita

A single case suggests a possible benefit, but confounding factors and the off-label setting temper the conclusions.

• by Andrea Surnit

• June 15, 2026

• 4 min